RA Capital Nexus Fund Iii, LP

Director RA Capital Management adds 32,876 shares at $8.89 avg amid 5 rapid buys in 16 days; stock +48.8% in 90d.

RA Capital Management, LP filed Form 4 on 2026-06-25 reporting 2 separate purchases totaling 32,876 shares for $292,126.48 at a blended average price of $8.89 per share on 2026-06-25 and 2026-06-26. This transaction is the most recent of 5 consecutive buy transactions by the same director at ARTV executed over a 16-day window (2026-06-10 through 2026-06-25), with holdings expanding from 16.76M to 16.80M shares. Notably, ARTV trades at $9.58 currently, representing +48.8% gains over 90 days and +20.8% over 30 days, though the company is deeply unprofitable (latest quarter revenue of $251.0K, net loss of $-23.5M) and reported -100.0% annual revenue growth. The cross-ticker track record shows RA Capital's prior 20 open-market buys averaged +2.7% 30-day returns, but prior outcomes at ARTV are not yet measurable given the recent timing of all 5 purchases in this cluster.

Director RA Capital Management buys 531,326 shares at $8.66 avg over 3 days despite stock down 8.9% in 30 days; stock still -38.7% from 52-week high.

RA Capital Management filed a Form 4 disclosing 3 separate purchases totaling 531,326 shares for $4,599,903.46 across a three-day window (June 12–16, 2026), with a blended average price of $8.66. The transactions increased the director's holding to 16,763,043 shares from 16,231,717 shares. Notably, this purchase occurred as the stock was trading -38.7% from its 52-week high of $14.53 and down 8.9% over the prior 30 days, though it has rebounded 53.6% over 90 days. The company is unprofitable with a quarterly revenue of $251,000 and full-year net income of -$23,516,000; annual revenue growth is -100.0%, indicating a material revenue decline. The director's prior purchase at ARTV (May 11, 2026) delivered a 90-day return of -30.6%, suggesting this ticker has not aligned with the director's cross-ticker buy success rate (93.33% 90-day win rate across all open-market holdings). The accumulation during a price decline and amid negative fundamentals warrants attention to whether this represents a conviction signal or portfolio mechanics.

RA Capital Management director acquired 21,188,750 shares ($423.8M) at $20.00 in PIPE placement at PBLS IPO.

RA Capital Management, LP, acting as director of Parabilis Medicines, completed 2 separate share purchases totaling 21,188,750 shares (21.19M shares) for $423,775,000.00 ($423.8M) at $20.00 per share on June 11, 2026. This transaction is a private placement (PIPE) allocation tied to PBLS's recent IPO, not a discretionary open-market purchase, so it reflects allocation participation rather than a conviction-driven buying signal. The company is trading at $25.01 as of June 15, 2026—four trading days after listing—representing modest outperformance versus the $20.00 subscription price. RA Capital's post-transaction non-derivative holdings of 2,648,278 shares reflect only a portion of the investor's total position; earlier preferred stock holdings are no longer reflected post-transaction, indicating conversion or redemption as part of the IPO transition.

RA Capital Management accumulates 1,027,722 shares in 3 purchases (June 9-11) at $7.44 average; stock down -24.7% in 30 days vs. -44.9% from 52-week high.

RA Capital Management, LP filed Form 4 disclosing 3 separate purchases totaling 1,027,722 shares for $7,650,148.29 at a blended average price of $7.44. The insider now holds 16,231,717 shares post-transaction, a +6.8% increase. At current price of $8.00, the stock is -24.7% over 30 days and -44.9% from its 52-week high of $14.53. The company reported latest quarterly revenue of $251,000.00, annual revenue growth of -100.0%, and net income of $-23,516,000.00, indicating a deeply unprofitable position with materially contracted revenue. This accumulation occurs while ARTV trades near mid-range of its 52-week spread and after the insider's prior buy on 2026-05-11 experienced a -35.6% loss over 30 days. The cross-ticker track record shows 93.33% accuracy on prior buys with +5.9% average 30-day returns, but the same-ticker history is unfavorable: 0 of 1 prior buys at ARTV were well-timed at the 90-day mark.

Ra Capital Management increases stake in ARTV by 75% with ~$75M open-market purchase; first buy at this company in 36 months.

Ra Capital Management, a board director and major shareholder, deployed approximately $75 million to acquire a substantial block of Artiva shares, expanding its indirect stake by more than 75 percent—the largest single acquisition in the fund's 36-month filing history at this company. The purchase occurred while the stock trades well below its 52-week high and follows a dramatic rally over the prior quarter, yet the company remains unprofitable with revenues declining sharply and significant annual net losses. Notably, this represents Ra Capital's first open-market purchase of ARTV shares on record, despite the fund's extensive trading activity across other holdings over the past three years—suggesting a deliberate shift toward this particular investment after a period of inactivity. The timing and scale of the buy are notable given the stock's weak fundamentals, though Ra Capital's prior open-market purchases across its broader portfolio have demonstrated a strong track record of capturing upside gains within 90 days.

RA Capital Management (Director) buys 369,000 shares for $8.8M at $23.75 avg; stock now $27.09, down 25.4% in 90 days.

RA Capital Management, L.P. executed 2 separate purchases totaling 369,000 shares for $8,762,797.00 (blended average $23.75 per share) on March 27 and March 30, 2026, increasing holdings by 6.8% to 5,825,521 shares post-transaction. The buyer's cross-ticker track record shows strong prior buy performance with average 90-day returns of +69.8% and a 100% win rate across 13 prior open-market purchases, though Mineralys specifically shows a recent 90-day decline of -25.4% from the transaction window, substantially exceeding the broader market weakness. The company posted a full-year net income of $-36,932,000.00, operating unprofitably; the $8.8M deployment into an unprofitable biotech at a 6.8% portfolio increase by a major director-level holder warrants attention to whether this reflects conviction in near-term recovery or pipeline inflection versus defensive positioning in a distressed position.

RA Capital Management (Director) acquired 300,000 shares of BCAX at $16.00 for $4.8M, bringing total holdings to 4.60M shares

RA Capital Management purchased 300,000 shares at $16.00, expanding its position by 7.0% to 4.60M shares. The acquisition occurred when BCAX trades at $17.59, 8.0% below its 52-week high of $19.11 and reflecting a 4.7% gain over the prior 30 days. This is material given RA Capital's scale as a director-level stakeholder. However, contextual signals are mixed: Bicara is unprofitable with a net income of -$36.3M over its most recent full fiscal year, which limits the comfort level of the buy. Across RA Capital's full cross-ticker open-market history, prior buys averaged a 30-day return of 53.2%, but its prior sells have been poorly timed (average 90-day return +3.5% and well-timed rate 0.00%), suggesting mixed predictive skill. This transaction adds data but does not constitute sufficient evidence of exceptional conviction at BCAX specifically.

RA Capital Management (Director) purchased 3,690,000 shares for $59,040,000.00 at $16.00 on 2026-02-09; concurrent cluster buy by 14 insiders in 14 days.

RA Capital Management, L.P., as a director, deployed $59,040,000.00 across 2 separate purchases totaling 3,690,000 shares at $16.00 per share on 2026-02-09. The current price of $27.55 reflects a 72% markup from transaction price, though given SGP's recent listing (4 trading days), this price movement may reflect initial volatility rather than fundamental reassessment. Notably, 14 other insiders also purchased shares within the same 14-day window, establishing a cluster buy pattern that suggests aligned conviction among multiple stakeholders at the same price point. The filing flagged derivative securities conversion activity; this Table I position of 2,054,678 shares post-transaction does not represent the insider's total holding and should not be read as a near-complete position exit.

RA Capital Management purchased 7,111 shares of CLYM at $3.50 on 2026-01-05, growing position to 3,403,429 shares amid unprofitable fundamentals.

RA Capital Management acquired 7,111 shares at $3.50, a relatively small incremental addition to an already substantial 3.40M-share position, at a price 16.7% below the current market price of $4.20. The purchase follows two prior buys at the same ticker within days (2025-12-11 and 2025-12-12), suggesting repeated accumulation despite Climb Bio's unprofitable fundamentals—the company reported a net loss of $12.9M over its most recent full fiscal year. The stock has recovered sharply (+132.0% over 30 days, +122.2% over 90 days) from a 52-week low of $1.13, yet remains -14.8% from its 52-week high of $4.93. The insider's broader cross-ticker history shows 2 prior buys against 18 prior sells with a modest +4.5% average 30-day return following sales, which does not establish a strong pattern of timing acumen at this specific ticker.

Director RA Capital Management purchases 314,561 shares in 2 tranches at $2.18–$2.86; stock now at $3.81, up 100.5% in 30 days.

RA Capital Management, a Director, executed 2 separate purchases totaling 314,561 shares for $754,737.14 at prices ($2.18 and $2.86) well below the current price of $3.81, expanding holdings by 10.2% to 3,396,318 shares. The timing coincides with exceptional recent momentum: the stock has rallied 100.5% over the prior 30 days and 89.6% over 90 days, now sitting at its 52-week high. However, this purchase occurs against a backdrop of ongoing unprofitability ($-12,888,000.00 net income) and the insider's cross-ticker track record shows 20 prior sells with no offsetting buys recorded in the summarized history. The filing reflects a director's discretionary accumulation during a period of sharp stock appreciation, warrant deeper examination into whether this represents conviction in the company's turnaround or a specific investment thesis distinct from the broader momentum.